|
|
|
|
GeoVax Labs provides update on vaccine trials progress
- US biopharmaceutical company GeoVax Labs Inc (OTC: GOVX) gave yesterday an update on its vaccine trials progress.CEO Robert McNally said that the HIV/AIDS population continues to grow at an alarming rate, 60,000 new infections annually, and that's...
|
|
|
GeoVax Labs, Inc. Begins Enrollment At Final Site For Preventative Vaccine; Next Step Is To Submit IND Application For Therapeutic Vaccine To FDA
GeoVax Labs, Inc.(OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, provided an update on its vaccine ...
|
|
|
GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA
ATLANTA, Feb.8 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX.OB) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its antibody...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
(GlobeNewswire via COMTEX) ----XOMA Ltd.(Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its antibody...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA - News), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical ...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052
BERKELEY, Calif., Feb.9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA - News), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical ...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of...
|
|
|
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
BERKELEY, Calif., Feb.9, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its antibody...
|
|
|
GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA (AEGiS)
GeoVax Labs, Inc.Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA PRNewswire - February 8, 2010 http://www.aegis.org/news/pr/2010/PR100210.html -- Hires Clinical Research...
|
|
|
Stem Cell Therapeutics Corp. Announces the Third and Final Positive Review by the Data Safety and Monitoring Board for the Modified REGENESIS Phase IIb Stroke Trial
(MARKETWIRE via COMTEX) ----Stem Cell Therapeutics Corp.("SCT" or the "Company") (TSX VENTURE: SSS) announced today it has been advised by the Data Safety Monitoring Board ("DSMB") that its third and final regularly scheduled safety analysis has been...
|
|
|
Stem Cell Therapeutics Corp. Announces the Third and Final Positive Review by the Data Safety and Monitoring Board for the Modified REGENESIS Phase IIb Stroke Trial
CALGARY, ALBERTA--(Marketwire - Feb.9, 2010) - Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE: SSS) announced today it has been advised by the Data Safety Monitoring Board ("DSMB") that its third and final regularly scheduled safety...
|
|
|
Keryx Biopharmaceuticals (NASDAQ: KERX) Responds To Erroneous Report About Planned Phase III Study For Patient
Keryx Biopharmaceuticals (NASDAQ: KERX) Responds To Erroneous Report About Planned Phase III Study For Patients With Colorectal Medical Medical Medical Worldwide Search / Oncology hip Funny Useful Websites Compare and save on surgery Medical and ...
|
|
|
XOMA (XOMA) Begins Enrollment for XOMA 052 Phase 2b
XOMA Ltd.(NASDAQ: XOMA) announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its antibody candidate, XOMA 052, in Type 2 diabetes patients. The randomized, placebo-controlled trial will be...
|
|
|
Penwest Initiates Second Phase IIa Clinical Trial for A0001
PATTERSON, N.Y., Feb.9, 2010 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. today announced that it has initiated a Phase IIa clinical trial for A0001 in patients with the A3243G mitochondrial DNA point mutation and evidence of impaired...
|
|
|
Stem Cell Therapeutics Corp. Announces the Third and Final Positive Review by the Data Safety and Monitoring B
MARKETWIRE Stem Cell Therapeutics Corp.('SCT' or the 'Company') (TSX VENTURE: SSS) announced today it has been advised by the Data Safety Monitoring Board ('DSMB') that its third and final regularly scheduled safety analysis has been completed and the DSMB...
|
|
|
Cerus Corporation Reports Positive Outcome Of Phase 1 Clinical Trial Of INTERCEPT Red Blood Cells
Cerus Corporation (NASDAQ:CERS) announced today that its Phase 1 trial of red blood cells treated with the INTERCEPT Blood System met its primary endpoint, with preliminary analysis demonstrating that greater than 75 percent of treated cells...
|
|
|
Cerus Corporation Reports Positive Outcome of Phase 1 Clinical Trial of INTERCEPT Red Blood Cells
Data Supports Advancement of Product Development CONCORD, Calif.--(BUSINESS WIRE)--Feb 9, 2010 - Cerus Corporation (NASDAQ:CERS) announced today that its Phase 1 trial of red blood cells treated with the INTERCEPT Blood System met its primary...
|
|
|
Stem Cell Therapeutics Corp. Announces the Third and Final Positive Review by the Data Safety and Monitoring B
CALGARY, ALBERTA -- (MARKET WIRE) -- 02/09/10 -- Stem Cell Therapeutics Corp.('SCT' or the 'Company') (TSX VENTURE: SSS) announced today it has been advised by the Data Safety Monitoring Board ('DSMB') that its third and final regularly scheduled safety...
|
|
|
Stem Cell Therapeutics Corp. Announces the Third and Final Positive Review by the Data Safety and Monitoring Board for the Modif
(Marketwire via COMTEX) -- Stem Cell Therapeutics Corp.("SCT" or the "Company") (TSX VENTURE: SSS | Quote | Chart | News | PowerRating) announced today it has been advised by the Data Safety Monitoring Board ("DSMB") that its third and final regularly...
|
